
Marike Gabrielson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3914091/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. International Journal of Epidemiology, 2022, 50, 1897-1911.	1.9	43
2	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
3	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
4	Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer. Translational Oncology, 2022, 17, 101339.	3.7	1
5	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
6	Topical Endoxifen for Mammographic Density Reduction—A Randomized Controlled Trial. Oncologist, 2022, 27, e597-e600.	3.7	5
7	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
8	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719.	6.3	14
9	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
10	Predictors of mammographic microcalcifications. International Journal of Cancer, 2021, 148, 1132-1143.	5.1	8
11	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
12	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Journal of Clinical Oncology, 2021, 39, 1899-1908.	1.6	33
13	Mammographic microcalcifications and risk of breast cancer. British Journal of Cancer, 2021, 125, 759-765.	6.4	32
14	Mammographic Density Change and Risk of Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 391-399.	6.3	32
15	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
16	Hormonal determinants of mammographic density and density change. Breast Cancer Research, 2020, 22, 95.	5.0	20
17	Inclusion of Endogenous Plasma Dehydroepiandrosterone Sulfate and Mammographic Density in Risk Prediction Models for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 574-581.	2.5	6
18	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32

MARIKE GABRIELSON

#	Article	IF	CITATIONS
19	PGC1α and VDAC1 expression in endometrial cancer. Molecular and Clinical Oncology, 2020, 14, 42.	1.0	5
20	Interval breast cancer is associated with other types of tumors. Nature Communications, 2019, 10, 4648.	12.8	25
21	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
22	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
23	Determinants of Mammographic Density Change. JNCI Cancer Spectrum, 2019, 3, pkz004.	2.9	27
24	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
25	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
26	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
27	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
28	The <i>BRCA2</i> c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
29	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	1.9	88
30	Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. Breast Cancer Research, 2018, 20, 14.	5.0	8
31	Association of reproductive history with breast tissue characteristics and receptor status in the normal breast. Breast Cancer Research and Treatment, 2018, 170, 487-497.	2.5	15
32	Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky055.	2.9	16
33	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
34	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nature Genetics, 2017, 49, 834-841.	21.4	426
35	Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA). International Journal of Epidemiology, 2017, 46, 1740-1741g.	1.9	88
36	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099

MARIKE GABRIELSON

#	Article	IF	CITATIONS
37	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
38	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	1.8	9
39	Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues. Breast Cancer Research and Treatment, 2016, 158, 253-261.	2.5	17
40	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
41	Altered PPARγ Coactivator-1 Alpha Expression in Abdominal Aortic Aneurysm: Possible Effects on Mitochondrial Biogenesis. Journal of Vascular Research, 2016, 53, 17-26.	1.4	15
42	Mitochondrial regulation of cell cycle progression through SLC25A43. Biochemical and Biophysical Research Communications, 2016, 469, 1090-1096.	2.1	11
43	Expression of Mitochondrial Regulators PGC1α and TFAM as Putative Markers of Subtype and Chemoresistance in Epithelial Ovarian Carcinoma. PLoS ONE, 2014, 9, e107109.	2.5	35
44	The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines. Oncology Reports, 2013, 29, 1268-1274.	2.6	7
45	The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. BMC Cancer, 2012, 12, 350.	2.6	16
46	Inhibition of Hedgehog Signaling Decreases Proliferation and Clonogenicity of Human Mesenchymal Stem Cells. PLoS ONE, 2011, 6, e16798.	2.5	47